Darolutamide plus chemo and hormone therapy before prostate surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of three treatments (darolutamide, docetaxel, and hormone therapy) given before surgery for men with locally advanced prostate cancer that hasn't spread. The goal is to see if this approach is safe and effective in shrinking the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 75 years old.
- You have prostate cancer that has not spread beyond the pelvis (locally advanced) and you plan to have surgery to remove your prostate.
- You are in good physical condition (able to do daily activities without help) and expected to live at least 10 more years.
- Your blood tests (kidney, liver, blood counts) are within certain limits.
- You have not had any previous treatment for prostate cancer (like radiation, chemo, or hormone therapy).
- You are not taking strong pain medicines for cancer pain and do not have any condition that would affect taking oral medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of a targeted radioactive drug (177Lu-PSMA-617) and a hormone blocker (Darolutamide) given before surgery for high-risk prostate cancer that hasn't spread. The goal is to see if this approach can improve outcomes.
This study looks at combining a drug called darolutamide with standard hormone therapy for men whose prostate cancer has spread to the lymph nodes after surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.